CTRI/2020/12/029581
Not yet recruiting
未知
A study of renal manifestations and its outcome in hospitalised patients with Covid 19 at a tertiary care hospital in Dakshina Kannada ,Karnatak - ROCD
nil0 sites0 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereHealth Condition 2: B972- Coronavirus as the cause of diseases classified elsewhereHealth Condition 3: B338- Other specified viral diseases
- Sponsor
- nil
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •All patients diagnosed with covid 19 including children either by RT\-PCR or rapid antigen test admitted in our hospital.
Exclusion Criteria
- •Case files where urinary analysis and kidney function evaluation reports are not present.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
Renal complications of Amikacin in patients with neonatal sepsisIRCT20201212049686N1Tehran University of Medical Sciences90
Recruiting
Not Applicable
The analysis of renal complication associated with Rheumatoid ArthritisRheumatoid ArhtritisJPRN-UMIN000032529Toranomon hospital120
Completed
Not Applicable
Influence of renal dysfunction on the outcomes of hepatectomy for hepatocellular carcinomaJPRN-UMIN000041749Hiroshima University238
Active, not recruiting
Phase 1
Evaluation of the impact of renal function on the pharmacokinetics of hydroxyurea (Siklos®) in patients with sickle cell disease with normal renal function, with hyperfiltration, or with renal failure. DARH studySiklos is indicated for the prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in adults, adolescents and children older than 2 years suffering from symptomatic sickle cell syndrome.MedDRA version: 17.1Level: LLTClassification code 10040643Term: Sickle cell crisisSystem Organ Class: 100000004851Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2014-005033-31-FRAddmedica S.A.S
Active, not recruiting
Phase 1
A study to assess the renal function in young male patients with Fabry disease who have never received any specific treatment for this disease.Fabry diseaseMedDRA version: 15.0Level: PTClassification code 10016016Term: Fabry's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]EUCTR2012-001966-14-ESGenzyme, a Sanofi Company39